Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER2/CD3/CD28 Tri-specific antibody SAR443216

A tri-specific T-cell engager and monoclonal antibody targeting the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), CD3, a T-cell surface antigen, and CD28, a T-cell specific surface glycoprotein and co-stimulatory molecule, with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-HER2/CD3/CD28 tri-specific antibody SAR443216 targets and binds to CD3 and CD28 on T cells and HER2 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against HER2-expressing tumor cells. HER2, a receptor tyrosine kinase (RTK) mutated or overexpressed in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.
Synonym:anti-CD3xCD28xHER2 trispecific antibody SAR443216
CD3xCD28xHER2 trispecific T-cell engager SAR443216
tri-specific T-cell engager SAR443216
Code name:SAR 443216
SAR-443216
SAR443216
Search NCI's Drug Dictionary